Background
• Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have revolutionized the care of patients with melanoma and many other tumor types
• Recently, the immunoregulatory pathway comprising LAG-3 and its ligands became the third immune checkpoint pathway for which blockade demonstrated a progression-free survival benefit in a phase III clinical trial (RELATIVITY-047)¹

Aim
• To explore oncology healthcare professionals’ (HCPs’) familiarity with anti–LAG-3 mechanism of action, FDA-approved indications, and identification and management of associated adverse events

Methods
• CCO conducted a series of 10 CME/CE/CPE-certified live educational activities for HCPs and 1 ongoing, on-demand activity; data shown are for March - September 2022 (N = 356)
• Each activity included polling questions designed to assess key aspects of HCP knowledge of LAG-3 and LAG-3-directed therapies

Conclusions
• HCPs’ knowledge of LAG-3–targeted therapy is limited
  o Pre-education, 33% correctly identified LAG-3 mechanism of action and 28% correctly identified the current FDA indication for relatlimab/nivolumab
• HCPs are not confident in identifying and managing adverse events associated with approved LAG-3 combination therapy
  o Pre-education, 25% were confident increasing to 70% after education
• More education on LAG-3 therapy would increase HCPs’ knowledge and confidence to implement this new option for treating patients with advanced melanoma and other cancers

References